Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/11/2017
SIETES contiene 92130 citas

 
 
 1 a 20 de 509 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Lee-HY, Ban G-Y, Jeong C-G, Lee JH, Park SH, Kim SH, Lee Y-H, Ye Y-M. Propacetamol poses a potential harm of adverse hypotension in male and older patients. Pharmacoepidemiol Drug Saf 2017;26:256-64. [Ref.ID 102062]
2. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
3.Tiene citas relacionadas
Wang C, Wong S, Graham DJ. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232-3. [Ref.ID 100367]
4.Tiene citas relacionadas
DeLoughery TG. Risk of anaphylaxis with intravenous iron products. JAMA 2016;315:2232. [Ref.ID 100366]
5.Tiene citas relacionadas Cita con resumen
Pathan SA, Mitra B, Straney LD, Afzal MS, Anjum S, Shukla D, Morley K, Al Hilli SA, Al Rumaihi K, Thomas SH, Cameron PA. Delivering safe and effective analgesia for management of renal colic in the emergency department: a double-blind, multigroup, randomised controlled trial. Lancet 2016;387:1999-2007. [Ref.ID 100295]
6.Tiene citas relacionadas
Knoedler JJ, Lieske JC. Non-steroidal anti-inflammatory drugs for renal colic. Lancet 2016;387:1971-2. [Ref.ID 100294]
7. Cita con resumen
Jian Z, Li H, Race NS, Ma T, Jin H, Yin Z. Is the Era of intravenous proton pump inhibitors coming to an end in patients with bleeding peptic ulcers? meta-analysis of the published literature.. Br J Clin Pharmacol 2015:18 de diciembre. [Ref.ID 99821]
8.Tiene citas relacionadas
Connors JM. Antidote for factor Xa anticoagulants. N Engl J Med 2015;373:2471-2. [Ref.ID 99801]
9.Tiene citas relacionadas Cita con resumen
Wang C, Graham DJ, Kane RC, Xie D, Wemecke M, Levenson M, MaCurdy TE, Houstoun M, Ryan Q, Wong S, Mott K, Sheu T-C, Limb S, Worrall C, Kelman JA, Reichman ME. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA 2015;314:2062-8. [Ref.ID 99687]
10.Tiene citas relacionadas Cita con resumen
Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015;373:2413-24. [Ref.ID 99658]
11. Cita con resumen
Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, COPOUSEP investigators West Network for Excellence in Neuroscience. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet 2015;386:974-81. [Ref.ID 99529]
12. Cita con resumen
Sánchez-González R, Ternavasio-de la Vega H, Moralejo Alonso L, Revuelta SI, Fuertes Martín A. Hipofosfatemia asociada a la administración intravenosa de hierro carboximaltosa en pacientes con anemia ferropénica. Un efecto secundario frecuente. Med Clin (Barc) 2015;145:108-11. [Ref.ID 99378]
13. Cita con resumen
Anónimo. Drug-administering pump can be hacked, FDA warns. DIA Daily 2015:1. [Ref.ID 99372]
14. Cita con resumen
Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, Carr AJ. Osteoarthritis. Lancet 2015;386:376-87. [Ref.ID 99368]
15. Cita con resumen
Freedberg DE, Salmasian H, Abrams JA, Green RA. Orders for intravenous proton pump inhibitors after implementation of an electronic alert. JAMA Intern Med 2015;175:452-4. [Ref.ID 98971]
17. Cita con resumen
Anónimo. Peramivir (Rapivab): an IV neuraminidase inhibitor for treatment of influenza. Med Lett Drugs Ther 2015;57:17-9. [Ref.ID 98855]
18. Cita con resumen
Anónimo. Oritavancin (Orbactiv) for skin and skin structure infections. Med Lett Drugs Ther 2015;57:3-5. [Ref.ID 98698]
19. Cita con resumen
Anónimo. FDA approves Rapivab to treat flu infection. FDA U.S. Food and Drug Administration 2014:1. [Ref.ID 98394]
20. Cita con resumen
Anónimo. FDA approves Orbactiv to treat skin infections. FDA U.S. Food and Drug Administration 2014:6 de agosto. [Ref.ID 97853]
Seleccionar todas
 
 1 a 20 de 509 siguiente >>